Masayuki Kanamori

12PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCognitive neuroscienceCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 21, 2026
CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma.

|May 12, 2026
Tectal glioma with pilocytic astrocytoma morphology carrying a histone H3 K27M mutation and malignant transformation: a literature review.

|Jan 30, 2026
Long-term intelligence after high-dose radiotherapy to the primary site versus chemotherapy and whole-ventricle radiotherapy in patients with germinoma.

Masayuki Kanamori, Yumi Sugawara, Yoshiteru Shimoda

|May 16, 2025
A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol.

Yoshihiro Muragaki, Eiichi Ishikawa, Manabu Tamura

|Dec 11, 2024
Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study.

Masayuki Kanamori, Shunsuke Tsuzuki, Ichiyo Shibahara

|Nov 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection.

Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda

Pageof 2

Frequent Collaborators

3 joint publications

Yoshiki Arakawa

2 joint publications

Fumiyuki Yamasaki

2 joint publications

Yoshitaka Narita

1 joint publications

Naoko Mori